logo
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

Globe and Mail21-07-2025
Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.
Despite the loss of exclusivity ('LOE') of its multi-billion-dollar product, Stelara, J&J's Innovative Medicines unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. Importantly, its MedTech segment also outperformed expectations. Sales in the MedTech segment improved from the first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China.
J&J also raised its sales and EPS guidance for the year to reflect a strong operational performance coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. The tariff costs are exclusively related to its MedTech unit.
In response to the earnings beat and guidance raise, J&J's shares rose more than 6% on July 16, reflecting investors' renewed optimism for the stock. However, a single quarter's results are not so important for long-term investors, and the focus should rather be on the company's strong fundamentals. Let's understand the company's strengths and weaknesses to better analyze how to play J&J stock in the post-earnings scenario.
J&J's Diversified Business Model
Johnson & Johnson's biggest strength lies in its diversified business model as it is the only major health care company operating in both the medical devices and pharmaceutical sectors. In 2023,J&J separated its Consumer Health business into a newly listed company called Kenvue KVUE. The separation of Kenvue allowed J&J to focus on its core pharmaceutical and medical device business.
It has more than 275 subsidiaries, indicating that the business is extremely well-diversified. This diversification helps withstand economic cycles more effectively. J&J has 26 platforms with annual sales exceeding $1 billion. Its diversified business is allowing it to post top-line growth in 2025, despite LOE for a blockbuster drug like Stelara. Meanwhile, it has one of the largest R&D budgets among pharma companies.
JNJ's Innovative Medicine Unit: A Bright Spot
J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 2.4% in the second quarter of 2025 on an organic basis despite LOE for Stelara and the negative impact of the Part D redesign. J&J expects continued growth in the second half of 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications for Tremfya and Rybrevant.
J&J expects to generate more than $57 billion in sales in the Innovative Medicines segment in 2025. It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030. J&J mentioned on the second-quarter conference call that it expects its oncology sales to be more than $50 billion by 2030 — quite an optimistic target in our view.
Moreover, J&J believes 10 of its new Innovative Medicine products have the potential to deliver peak sales of $5 billion, including new cancer drugs like Talvey and Tecvayli, a newly acquired drug, Caplyta and pipeline candidates like nipocalimab, TAR-200 and icotrokinra (JNJ-2113).
Nipocalimab was approved under the name Imaavy in April for treating generalized myasthenia gravis. TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. Caplyta was added with the Apil acquisition of Intra-Cellular Therapies.
J&J's MedTech Segment Shows Improvement in Q2
J&J's MedTech segment sales rose 6.1% on an operational basis in the second quarter, improving from the first-quarter levels, driven by the newly acquired cardiovascular businesses, Abiomed and Shockwave, as well as in Surgical Vision and wound closure in Surgery. Moreover, improvements in J&J's electrophysiology business also drove sequential growth. In the MedTech segment, increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth in the second half. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025.
However, the company continues to face headwinds in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program. VBP is a government-driven cost containment effort in China. J&J expects continued impacts from VBP issues in China in 2025 as the program continues to expand across provinces and products.
Patent Expiration of J&J's Blockbuster Drug Stelara & Other Headwinds
J&J lost U.S. patent exclusivity of Stelara in 2025. The drug generated sales of $10.36 billion in 2024. The launch of generics is significantly eroding the drug's sales and hurting J&J's sales and profits in 2025. Stelara sales declined 42.7% in the second quarter of 2025.
Several biosimilar versions of Stelara have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases.
In addition, sales in 2025 are being hurt by the impact of the Medicare Part D redesign.
J&J's Talc Suits & Pharma Tariffs Remain an Overhang
J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder.
In April, a bankruptcy court in Texas rejected J&J's proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J will go back to the traditional tort system to fight the lawsuits individually with its bankruptcy strategy to settle the lawsuits failing for the third time.
The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again threatened to impose heavy tariffs, as high as 200%, on pharmaceutical imports. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are imposed.
J&J has already committed to boosting manufacturing in the United States and has a plan to invest $55 billion over the next four years to ensure that all medicines consumed in the United States are manufactured domestically.
J&J Stock Price, Valuation and Estimates
J&J's shares have outperformed the industry year to date. The stock has risen 15.1% in the year-to-date period against a 0.5% decline for the industry. The stock has also outperformed the sector and the S&P 500 Index, as seen in the chart below.
JNJ Stock Outperforms Industry, Sector & S&P 500
From a valuation standpoint, J&J is slightly expensive. In terms of the price/earnings ratio, the company's shares currently trade at 14.74 forward earnings, slightly higher than 14.71 for the industry. The stock is, however, trading below its five-year mean of 15.70.
JNJ Stock Valuation
The Zacks Consensus Estimate for 2025 earnings has risen from $10.64 per share to $10.83 over the past seven days, while that for 2026 has risen from $11.09 to $11.33 over the same timeframe.
JNJ Estimate Movement
Consider Investing in J&J's Stock
J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J expects growth to accelerate from 2026 onward.
J&J is also rapidly advancing its pipeline, attaining significant clinical and regulatory milestones that will help drive accelerating growth through the back half of the decade. J&J has also been on an acquisition spree, with the latest acquisition of Intra-Cellular Therapies strengthening its presence in the neurological and psychiatric drug market.
In April, J&J's board authorized a 4.8% increase in its quarterly dividend, marking the company's 63rd consecutive year of dividend increase.
The Stelara patent cliff and the potential impact of Part D redesign will be significant headwinds in 2025. The uncertainty around the talc lawsuits and pharma tariffs lingers. However, the company looks quite confident that it will be able to navigate these challenges.
The stock's price appreciation this year, attractive valuation and rising estimates should encourage investors to bet on this Zacks Rank #2 (Buy) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
One Big Gain, Every Trading Day
To help you take full advantage of this market, you're invited to access every stock recommendation in all our private portfolios - for just $1.
Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That's about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.
Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
Kenvue Inc. (KVUE): Free Stock Analysis Report
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Teradyne Stock Soared 18.9% Today
Why Teradyne Stock Soared 18.9% Today

Globe and Mail

time20 minutes ago

  • Globe and Mail

Why Teradyne Stock Soared 18.9% Today

Key Points The company reported its Q2 earnings, beating most of Wall Street's targets. Guidance for Q3 EPS missed forecasts, but revenue projections suggest a second-half rebound driven by AI. 10 stocks we like better than Teradyne › Shares of Teradyne (NASDAQ: TER) jumped on Wednesday, finishing the day up 18.9%. The spike comes as the S&P 500 (^GSPC) and the Nasdaq Composite (^IXIC) fell slightly. Teradyne, an electronics testing company, released mostly better-than-expected earnings today, leading to a prominent analyst maintaining their "overweight" rating for the stock. Teradyne beats in the second quarter (mostly) The company's reported earnings per share (EPS) and revenue figures both slightly topped expectations. Analysts had estimated $0.54 per share on sales of $651 million. Teradyne delivered $0.57 per share on sales of $651 million. While the company surpassed expectations for the quarter, its top line fell by 11% year over year (YOY). Looking ahead, the company expects sales for Q3 of between $710 million and $770 million, above Wall Street targets. It did miss, however, on its EPS guidance. The company set a range of between $0.69 and $0.87, well below the expected $0.89. CEO Greg Smith said he expects AI-related testing to drive growth: "As we progress through the third quarter, we are gaining confidence in AI compute-related revenue inflecting in the second half of the year." Teradyne has room to grow Impressed by the performance and not phased by the lower-than-expected earnings guidance, Cantor Fitzgerald analysts maintained their Overweight rating, citing AI growth prospects. I agree. I think AI-related chip testing could drive major growth over the next few years. Should you invest $1,000 in Teradyne right now? Before you buy stock in Teradyne, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teradyne wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025

Carney concedes U.S. trade deal may not happen before Aug. 1 deadline
Carney concedes U.S. trade deal may not happen before Aug. 1 deadline

National Post

time20 minutes ago

  • National Post

Carney concedes U.S. trade deal may not happen before Aug. 1 deadline

Article content Border security was reportedly another sticking point from the U.S. perspective — more specifically fears around China using Canada 'as a platform to gain entry and influence in North America' beyond fentanyl, said the source. Article content Trump had originally pointed to the flow of fentanyl coming into the U.S. to impose 25 per cent tariffs on non-CUSMA compliant goods, but the idea that Canada is a large exporter of the deadly drugs to its southern border has been debunked by several analysts. Article content Trump has already struck deals with the United Kingdom, Indonesia, Vietnam and the Philippines, and more recently, with Japan and the European Union, which all include a relatively lower level of tariffs in exchange for several economic concessions. Article content Fen Osler Hampson, a professor of international affairs at Carleton University and co-chair of its expert group on Canada-U.S. relations, said Canada could benefit from taking its time in negotiating with its largest trading partner while Trump strikes more deal. Article content That way, he said, Canadian negotiators will be able to compare and contrast the bilateral trade deals Trump is making with other countries to get a lower tariff rate, and get more information about the pressure points they could use to strike the best deal possible. Article content 'It's what I call the last-mover advantage,' said Hampson, referring to a well-known business tactic which consists of the advantage a company has when it is the last to enter a market because it can learn from others' mistakes and improve on what already exists. Article content On Wednesday, Carney said Trump's revealed approach is to have a baseline tariff in certain strategic sectors to the U.S. economy, such as aluminum, steel, automobiles, pharmaceuticals, semiconductors, lumber and more, with 'very few relative exceptions.' Article content Hampson said the longer negotiations go on, the more pain American consumers will feel. Right now, they have been mostly shielded from its effects given that companies have either been stockpiling products or making up for the tariff loss in their profit margins. Article content 'These costs are going to start getting passed on to the American consumer. It's only a matter of time.' Article content

NorthWestern Energy Signs Letter of Intent to Serve Quantica Infrastructure's Montana Data Center Development
NorthWestern Energy Signs Letter of Intent to Serve Quantica Infrastructure's Montana Data Center Development

Globe and Mail

time20 minutes ago

  • Globe and Mail

NorthWestern Energy Signs Letter of Intent to Serve Quantica Infrastructure's Montana Data Center Development

NorthWestern Energy Group, Inc. d/b/a NorthWestern Energy (Nasdaq: NWE) today announced it has signed a letter of intent to provide energy services for Quantica Infrastructure's proposed data center development in Montana. NorthWestern Energy anticipates that service could be provided through its regulated business, pending further evaluation and regulatory considerations. This approach could improve cost efficiency by spreading the fixed costs of operating Montana-based energy infrastructure across a broader customer base. The projected Phase 1 energy service load is 500 megawatts, with phased growth to 1 gigawatt. Initial electric service could begin as early as 2026. The expected expansion to full Phase 1 of the data center development is 2030, depending on the progress of permitting, infrastructure development, and other planning activities. 'We're actively working with Quantica to optimize the transmission infrastructure and generation resources needed to support this project,' said Brian Bird, President and CEO of NorthWestern Energy. 'Montana's clean energy portfolio, reliable grid, and competitive rates make it an attractive location for new industries. This collaboration reflects our commitment to innovation, economic development, and delivering high-quality energy services.' 'We are excited to collaborate with NorthWestern to bring a shovel-ready, network-ready site for hyperscalers and AI that utilizes resilient power backed by dedicated renewable energy,' said John Chesser, CEO of Quantica Infrastructure. 'A project of this scale will create meaningful employment opportunities along with improvements in telecommunications and power infrastructure for Montanans.' NorthWestern Energy is currently conducting a transmission study to assess how best to meet Quantica's energy needs. Quantica has several generation projects in development, and a full energy supply solution would require a balanced portfolio of new resources—including both renewable and on-demand generation—along with infrastructure that integrates with the existing grid. This approach would help ensure reliability for Quantica's tenants while supporting grid stability and cost control for all customers. 'The scale of Quantica's projected energy demand presents an opportunity to improve overall system efficiency,' said Bleau LaFave, Vice President of Asset Management and Business Development at NorthWestern Energy. 'By delivering more kilowatt-hours across our system, we can better utilize our infrastructure and potentially reduce per-unit costs.' This project marks a meaningful step forward for Montana's economy and tech sector, underscoring the value of dependable energy service in drawing new investment to the state. Follow us on Facebook and LinkedIn and Instagram: @NorthWesternEnergy NorthWestern Energy - Delivering a Bright Future NorthWestern Energy Group, Inc., doing business as NorthWestern Energy, provides essential energy infrastructure and valuable services that enrich lives and empower communities while serving as long-term partners to our customers and communities. We work to deliver safe, reliable, and innovative energy solutions that create value for customers, communities, employees, and investors. We do this by providing low-cost and reliable service performed by highly-adaptable and skilled employees. We provide electricity and / or natural gas to approximately 842,100 customers in Montana, South Dakota, Nebraska, and Yellowstone National Park. Our operations in Montana and Yellowstone National Park are conducted through our subsidiary, NW Corp, and our operations in South Dakota and Nebraska are conducted through our subsidiary, NWE Public Service. We have provided service in South Dakota and Nebraska since 1923 and in Montana since 2002. Quantica Infrastructure Quantica is backed by EnCap Investments, a leading provider of growth capital to the independent sector of the U.S. energy industry since 1988.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store